Metformin treatment reduced CD11c and CD169 inhibition in PBMC of T2DM (P<0.05, Figures 3B,C) and reduced the increased expression of IL-6, iNOS, TNFα, and CD36 (Figures 3D–G). Here, SIGLEC1 is linked to type 2 diabetes mellitus.